ISU Abxis Valuation
Is A086890 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A086890 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A086890 (₩7070) is trading below our estimate of fair value (₩8766.8)
Significantly Below Fair Value: A086890 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A086890?
Other financial metrics that can be useful for relative valuation.
| What is A086890's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₩249.61b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.6x |
| Enterprise Value/EBITDA | 21.8x |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does A086890's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.2x | ||
A290650 L&C Bio | 9.7x | n/a | ₩469.6b |
A182400 NKMAX | 32.8x | n/a | ₩172.7b |
A256840 BNC Korea | 15.8x | n/a | ₩406.8b |
A251120 BIO-FD&CLtd | 22.4x | n/a | ₩125.1b |
A086890 ISU Abxis | 69.1x | 51.7% | ₩249.6b |
Price-To-Earnings vs Peers: A086890 is expensive based on its Price-To-Earnings Ratio (69.1x) compared to the peer average (20.2x).
Price to Earnings Ratio vs Industry
How does A086890's PE Ratio compare vs other companies in the Asian Biotechs Industry?
Price-To-Earnings vs Industry: A086890 is expensive based on its Price-To-Earnings Ratio (69.1x) compared to the Asian Biotechs industry average (32.8x).
Price to Earnings Ratio vs Fair Ratio
What is A086890's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 69.1x |
| Fair PE Ratio | 31.8x |
Price-To-Earnings vs Fair Ratio: A086890 is expensive based on its Price-To-Earnings Ratio (69.1x) compared to the estimated Fair Price-To-Earnings Ratio (31.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.